Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates
S. Pillet, P. S. Arunachalam, G. Andreani, N. Golden, J. Fontenot, P. Aye, K. Röltgen, G. Lehmick, C. Dube, P. Gobeil, S. Trepanier, N. Charland, M.-A. D'Aoust, K. Russell-Lodrigue, R. V. Blair, , N. Landry
This study evaluates the safety and immunogenicity of a plant-derived VLP vaccine against SARS-CoV-2 in non-human primates, finding that AS03 adjuvanted vaccine provides better protection and immune response.
bioRxiv · May 15, 2021Immunology